Upload
garran
View
24
Download
0
Tags:
Embed Size (px)
DESCRIPTION
Modern Management of heart Failure. Dr Amanda Varnava Consultant Cardiologist Watford & St Mary’s Hospitals. Background What is HF? How to diagnose? 4 stages of HF and Rx of these stages Specific therapies Prognosis SCD and prevention HF with normal systolic function Who manages care?. - PowerPoint PPT Presentation
Citation preview
Modern Management of heart Failure
Dr Amanda VarnavaConsultant Cardiologist
Watford & St Mary’s Hospitals
• Background• What is HF?• How to diagnose?• 4 stages of HF and Rx of these stages• Specific therapies• Prognosis• SCD and prevention• HF with normal systolic function• Who manages care?
Background
• Huge health costs $27 billion pa in US• Primarily a disease of the elderly• Incidence of 10/100 in those over 65yrs
What is heart failure?Impaired ventricular filling and / or
contraction
SignsSymptoms
Dyspnoea
Impaired ext tolerance
Fatigue
Fluid overload
3rd Heart sound
Assessment
• ECG• BNP• Echo• Non invasive testing for ischaemia • Angiogram
BNP assessment
3 questions we need addressed with echo
• Is EF preserved?• Is LV structure and wall movement normal?• Are there other structural abnormalities?
– Valvar disease– Atrial dilation– PA hypertension
Stages of Heart Failure
At risk Frank Heart Failure
At risk, but no evidence of structural disease or symptoms
Evidence of structural disease, but no symptoms
Structural disease with symptoms
Refractory symptoms
HT
CAD
Obesity
FH CM
Cardiotoxins
ETOH
1º Prevention
ACEIn/ARB
MI
Valvular disease
LVH
Dyspnoea
Fatigue
Ex Tol
ACEIn
Blockers
Spironolactone
±CRT
NYHA IV despite max Rx
Palliative care
Or
TX
LVADs
Stem cell Tx
Primary prevention
HT• Lifetime risk of HT is 75% • Optimal Rx of HT cuts in 1/2 the risk of HFDM• Females 3 x > likely to develop HF• ACEInCAD• All MI pts should start on ACEIn and • If HF > Add epeleronone
Management of asymptomatic pts
Drugs• ACEIn delay onset of symptoms and improve
mortality• No specific trials with ARBs• No trials with s, but ACC guidance suggests
use esp in CADDevices• MADIT II ICD trial supports use, but no’s huge
thus not current practice
Symptomatic patients
• As with asymptomatic• In addition diuretics for fluid overload• Aldosterone antagonistsAlso• Na restriction• Withdraw NSAIDS, Ca antag• Exercise• Close F/U
Refractory symptoms
• Increased awareness of palliative care
Where appropriate consider• Cardiac TX• LVADs• Stem cell Tx
Heart Failure Therapies
ACEIns
• Inhibit RAS at multiple sites• Start low, go slow• Probably class effect• Side effects related to kinin production
(cough ion 5-10%) and angioedema (1%) > common in Chinese and Blacks
Angiotensin Receptor Blockers
• Developed because of RAS “escape” with ACEIn and side effects
• However, less well studied and some benefits may relate to kinin production
• Thus alternative, not 1st line• Data is equivocal for ACEIn + ARB
Blockers
• Inhibit advrse effects of sympathetic NS• Trials with carvedilol, bisoprolol and LA
metoprolol• Not class effect• Rx as soon as HF diagnosed• If pts on low dose ACEIn greater benefit to
add’n of than ACEIn
Aldosterone antagonists
• Compensate for RAS escape with ACEIn• RALES study provided 30%mortality in
NYHA III/IV• EPESUS study showed 20% mortality post
MI with HF signs (eplerenone)
• Thus in mod-severe HF or HF post MI
Nitrate and Hydralazine
• Less well tolerated• Trials show inferior to ACEIn• Subgroup analysis showed benefit in black
pts when added to standard Rx
Digoxin
• No prognostic benefit• Can improve quality of life• Use in pts with persistent symptoms despite
standard Rx• Caution post MI / ongoing ischaemia
Cardiac resynchronisation therapy (CRT)
• Third of pts in NYHA III/IV have QRS>120ms (+electrical dysynchrony)
• Associated with suboptimal LV filling, prolonged MR and paradoxical septal motion
• Pacing both ventricles improves contractility and reduces MR
CRT cont’d
• When added to optimal drug Rx improves QOL, Ex Tol and hopitalisation
• Recent trials have also shown 20-30% mortality • However, many pts do not benefit thus other
discriminators echo TDI used to select pts
• Thus pts with persitent symptoms, wide QRS and echo dysynchrony
Prognosis
• Likelihood of survival can be reliably predicted for populations, but not individuals (death may be endstage HF or sudden)
• Old prognostic models do not apply due to new drug Rx and devices
• Annual mortality of 7% in those on
Sudden cardiac death
• Proportion with SCD is greater in those with less severe LVSD
• ICD trials show risk reduction 23-30% in pts with EF<35%
However,• Not within 1st 30 days post MI, no benefit
within 1st year and most trials did not inc large no’s of elderly
Heart failure with normal systolic function
Differential causes of signs of HF with normal EFIncorrect diagnosis
Incorrect assessment of LV function
Restrictive Cardiomyopathy
Pericardial constriction
Episodic systolic dysfunction (ischaemia, arrhythmias)
High output failure
Diastolic dysfunction
Management of diastolic dysfunction
• Few trials• Resolve fluid overload• Some data on ACEIn / ARBs• Treat underlying condition
Who should manage care?
Once diagnosed and appropriate investigations completed
Nurse led clinics
GP or specialist run service?1° care manage most ptsIf remain symptomatic or are complex then
refer to specialists